Want to see TOI full AI Analyst Report?
TOI Stock Chart & Stats
$3.85
-$0.01(-3.73%)
At close: 4:00 PM EST
$3.85
-$0.01(-3.73%)
Day’s Range― - ―
52-Week Range$2.32 - $6.67
Previous CloseN/A
Volume198.36K
Average Volume (3M)2.14M
Market Cap
$534.91M
Enterprise Value$599.49M
Total Cash (Recent Filing)$30.28M
Total Debt (Recent Filing)$104.86M
Price to Earnings (P/E)―
Beta1.70
Next Earnings
Aug 11, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding99,982,930
10 Day Avg. Volume2,491,830
30 Day Avg. Volume2,137,900
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)-209.23
Price to Sales (P/S)6.54
P/FCF Ratio-118.37
Enterprise Value/Market Cap1.12
Enterprise Value/Revenue1.10
Enterprise Value/Gross Profit7.41
Enterprise Value/Ebitda-20.51
Forecast
1Y Price Target
$8.50Price Target Upside120.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.15
Revenue Forecast (FY)$651.94M
Bulls Say, Bears Say
Bulls Say
Capitation And Value-Based ShiftA meaningful shift to capitated/value-based contracts increases recurring, per-member revenue and reduces pure volume sensitivity. Expanding delegated Medicare Advantage lives (~200k targeted) strengthens predictable cash flows and creates durable scale advantages for care management and utilization control.
Specialty Pharmacy ScaleRapidly growing specialty pharmacy is now the majority of revenue with scalable fill volumes and stable margins, creating a recurring cash flow engine. Large pharmacy scale supports better purchasing economics, cross-sell into clinic services, and leverage of fixed costs as the business grows.
Extended Debt Maturity / RefinancingReplacing near-term convertible notes with a longer-dated secured term loan materially extends maturities and eases immediate refinancing pressure. The longer runway improves near-term liquidity and gives management time to execute growth, margin and free-cash-flow initiatives.
Bears Say
Negative Stockholders' EquityNegative equity reflects accumulated losses and a thin capital cushion, increasing insolvency and refinancing sensitivity. This weakens financial flexibility, limits the company's ability to absorb shocks or invest opportunistically, and heightens reliance on sustained profitability to restore balance sheet health.
Persistent Negative Cash FlowConsistent operating and free cash flow deficits mean the business remains reliant on external capital or refinancing until FCF is sustainably positive. Historical cash burn raises execution risk: management must convert improved guidance into real cash to avoid dilutive or costly financing over the medium term.
Margin Compression And Pharmacy Pricing PressureMix shift to delegated contracts and pharmacy pricing headwinds (IRA phase‑in) have compressed unit economics. Lower revenue per fill and reduced patient services margins structurally pressure EBITDA conversion, making sustained margin improvement necessary to support profitability and deleverage the balance sheet.
Oncology Institute News
TOI FAQ
What was Oncology Institute, Inc.’s price range in the past 12 months?
Oncology Institute, Inc. lowest stock price was $2.32 and its highest was $6.67 in the past 12 months.
What is Oncology Institute, Inc.’s market cap?
Oncology Institute, Inc.’s market cap is $534.91M.
When is Oncology Institute, Inc.’s upcoming earnings report date?
Oncology Institute, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 22 days.
How were Oncology Institute, Inc.’s earnings last quarter?
Oncology Institute, Inc. released its earnings results on May 07, 2026. The company reported -$0.02 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.068.
Is Oncology Institute, Inc. overvalued?
According to Wall Street analysts Oncology Institute, Inc.’s price is currently Undervalued.
Does Oncology Institute, Inc. pay dividends?
Oncology Institute, Inc. does not currently pay dividends.
What is Oncology Institute, Inc.’s EPS estimate?
Oncology Institute, Inc.’s EPS estimate is -0.06.
How many shares outstanding does Oncology Institute, Inc. have?
Oncology Institute, Inc. has 99,982,930 shares outstanding.
What happened to Oncology Institute, Inc.’s price movement after its last earnings report?
Oncology Institute, Inc. reported an EPS of -$0.02 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went down -1.72%.
Which hedge fund is a major shareholder of Oncology Institute, Inc.?
Currently, no hedge funds are holding shares in TOI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oncology Institute Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.50 (120.78% Upside)
$8.50 (120.78% Upside)
Blogger Sentiment
Bullish
TOI Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 217.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $276.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.6%
Last 30 Days ▲ 35.9%
Last 30 Days ▲ 35.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
2.58%
Trailing 12-Months
Company Description
Oncology Institute, Inc.
The Oncology Institute (TOI) is a specialized healthcare provider delivering a full range of medical oncology services throughout the United States. Its comprehensive offerings include direct physician care, integrated on-site infusion and medication dispensing facilities, and advanced clinical trial management. The institute also provides radiation therapy, specialized outpatient programs for stem cell transplants and transfusions, and robust patient support services. Furthermore, TOI is actively involved in operating palliative care initiatives and overseeing clinical trials. These services are specifically designed to meet the needs of adult and senior cancer patients. The company maintains a significant operational footprint with 67 clinic locations. The Oncology Institute was established in 2007 and is headquartered in Cerritos, California.
TOI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial revenue growth (41% YoY), exceptional specialty pharmacy scale, capitation expansion and improved operating leverage drove better adjusted EBITDA and materially upgraded free cash flow guidance. Key operational milestones include Florida market profitability, planned expansion to ~200,000 delegated MA lives, and on-track AI and portal initiatives that are expected to further drive margins and ancillary capture. Headwinds include fee-for-service revenue decline, margin pressure in patient services due to ramping delegated contracts and seasonality in Q1, a reduction in average revenue per pharmacy fill, and refinancing/liquidity considerations. Overall, positive execution and upgraded cash flow outlook outweigh the manageable near-term margin and financing risks.View all TOI earnings summariesTOI Stock 12 Month Forecast
Average Price Target
$8.50
▲(120.78% Upside)
Technical Analysis
Ownership Overview
24.06% Insiders
7.06% Mutual Funds
0.01% Other Institutional Investors
60.29% Public Companies and
Individual Investors